Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Parathyroid Disorders Companies

Parathyroid disorders involve abnormalities in the function of the parathyroid glands, which are responsible for regulating calcium levels in the body. Companies involved in parathyroid disorders may focus on developing medications, diagnostic tools, and therapies to address conditions such as hyperparathyroidism or hypoparathyroidism.

Parathyroid Disorders Key Companies Latest Parathyroid Disorders Companies Update

November 2023: The EC approved YORVIPATH® (palopegteriparatide) as a replacement medication for people with persistent hypoparathyroidism, according to an announcement by Ascendis Pharma A/S. If you're using parathyroid hormone (PTH 1-34) prodrug, you should take it once a day. Ascendis is planning to commercialize YORVIPATH in Germany in January 2024, marking its first launch in the European Union (EU). There are major issues with health and quality of life for any patient dealing with chronic hypoparathyroidism. These individuals require innovative approaches to treatment that overcome the limitations and hazards of current standard medication, which mostly comprises of oral calcium and active vitamin D, in order to address the root cause of their ailment. For the treatment of individuals with persistent hypoparathyroidism, TransCon PTH, branded as YORVIPATH in the European Union, is a parathyroid hormone (PTH) replacement medication.

March 2022: The formation of Pathalys Pharma, Inc. was announced in March 2022. The company is a private, late-stage biopharma focused on developing and commercializing various best-in-class therapies for patients with chronic kidney disease (CKD). Initial seed financing for this formation came from DaVita Venture Group, which is a part of DaVita Inc., and Catalys Pacific. With the acquisition of upacicalcet, a unique clinical-stage asset, Pathalys gained exclusive rights to develop and market the medicine globally, except Japan and Asia, thanks to a license given by EA Pharma. The business is thrilled about the chance to collaborate with DaVita, a prominent player in the kidney care industry, to bring new treatments for patients with chronic kidney disease (CKD), starting with upacicalcet.List of Parathyroid Disorders Key companies in the market

Bayer Healthcare

Becton

Dickinson and Company

Eli Lilly, Ethicon, Inc.

Genentech

Medtronic

Merck

Mylan Laboratories

Novartis

Novo Nordisk

Pfizer

Roche

Smith & Nephew plc

Stryker

Teva Pharmaceutical Industries Ltd.

Zimmer Biomet Holdings, Inc.

Parathyroid Disorders Market Highlights:

Parathyroid Disorders Market Size

Parathyroid Disorders Market Trends

Parathyroid Disorders Market Analysis

Parathyroid Disorders Market Share

Parathyroid Disorders Market Highlights:

Parathyroid Disorders Market Trends

Parathyroid Disorders Market Analysis

Parathyroid Disorders Market Share

Parathyroid Disorders Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.